Atrial fibrillation burden, episode duration and frequency in relation to quality of life in patients with implantable cardiac monitor

Atrial fibrillation symptom reduction and improved quality of life following the hybrid convergent procedure: a CONVERGE trial subanalysis

Background

CONVERGE was a prospective, multicenter, randomized controlled trial that evaluated the safety of Hybrid Atrial Fibrillation Convergent (HC) and compared its effectiveness to endocardial catheter ablation (CA) for the treatment of persistent atrial fibrillation (PersAF) and longstanding PersAF (LSPAF). In 2020, we reported that CONVERGE met its primary safety and effectiveness endpoints. The primary objective of the present study is to report CONVERGE trial results for quality of life (QOL) and Class I/III anti-arrhythmic drug (AAD) utilization following HC.

Methods

Eligible patients had drug-refractory symptomatic PersAF or LSPAF and a left atrium diameter ≤6.0 cm. Enrolled patients were randomized 2:1 to receive HC or CA. Atrial Fibrillation Severity Scale (AFSS) and the 36-Item Short Form Health Survey (SF-36) were assessed at baseline and 12 months; statistical comparison was performed using paired t-tests. AAD utilization at baseline through 12 and 18 months post-procedure was evaluated; statistical comparison was performed using McNemar's tests.

Results

A total of 153 patients were treated with either HC (n=102) or CA (n=51). Of the 102 HC patients, 38 had LSPAF. AFSS and SF-36 Mental and Physical Component scores were significantly improved at 12 months versus baseline with HC overall and for the subset of LSPAF patients treated with either HC or CA. The proportion of HC patients (n=102) who used Class I /III AADs at 12 and 18 months was significantly less (33.3% and 36.3%, respectively) than baseline (84.3%; P<0.001). In LSPAF patients who underwent HC (n=38), AADs use was 29.0% through 18 months follow-up versus 71.1% at baseline (P<0.001).

Conclusions

HC reduced AF symptoms, significantly improved QOL, and reduced AAD use in patients with PersAF and LSPAF.

ClinicalTrialsgov Identifier

NCT01984346.

A Study of R-R Interval Transition Matrix Features for Machine Learning Algorithms in AFib Detection

Atrial Fibrillation (AFib) is a heart condition that occurs when electrophysiological malformations within heart tissues cause the atria to lose coordination with the ventricles, resulting in "irregularly irregular" heartbeats. Because symptoms are subtle and unpredictable, AFib diagnosis is often difficult or delayed. One possible solution is to build a system which predicts AFib based on the variability of R-R intervals (the distances between two R-peaks). This research aims to incorporate the transition matrix as a novel measure of R-R variability, while combining three segmentation schemes and two feature importance measures to systematically analyze the significance of individual features. The MIT-BIH dataset was first divided into three segmentation schemes, consisting of 5-s, 10-s, and 25-s subsets. In total, 21 various features, including the transition matrix features, were extracted from these subsets and used for the training of 11 machine learning classifiers. Next, permutation importance and tree-based feature importance calculations determined the most predictive features for each model. In summary, with Leave-One-Person-Out Cross Validation, classifiers under the 25-s segmentation scheme produced the best accuracies; specifically, Gradient Boosting (96.08%), Light Gradient Boosting (96.11%), and Extreme Gradient Boosting (96.30%). Among eleven classifiers, the three gradient boosting models and Random Forest exhibited the highest overall performance across all segmentation schemes. Moreover, the permutation and tree-based importance results demonstrated that the transition matrix features were most significant with longer subset lengths.

The results of health-related quality of life assessment depend on the prevailing rhythm at the assessment: Experience from the CAPTAF trial (Catheter Ablation Compared with Pharmacological Therapy for Atrial Fibrillation)

AIMS

To assess whether the prevailing rhythm at the time of replying to symptom and health-related quality of life (HR-QoL) questionnaires impacts the findings.

METHOD

A total of 150 patients from the randomized Catheter Ablation Compared with Pharmacological Therapy for Atrial Fibrillation-trial, comparing atrial fibrillation (AF) ablation versus drugs, were included. The effect of the prevailing rhythm on the outcome results of the HR-QoL 36-Item Short-Form Health Survey, the symptom severity questionnaire (SSQ), and the European Heart Rhythm Association (EHRA) score for classification of AF-related symptoms was assessed.

RESULTS

AF as the prevailing rhythm was independently associated with a significantly lower Vitality score; 18.4 points lower (95% confidence interval -32.7 to -4.1, p = .01) compared with sinus rhythm when adjusted for AF burden, median duration of episode, number of episodes, beta-blocker use, type of AF, and sex. The presence of AF did not affect the General Health score compared with sinus rhythm, nor did it influence symptoms assessed by the SSQ or EHRA score.

CONCLUSION

The observation that the presence of AF versus sinus rhythm when conducting HR-QoL tests had a negative impact on its outcome, leaving symptom-related questionnaires unaffected, implies that the prevailing rhythm should be taken into account when results of HR-QoL questionnaires are interpreted.